Journal
CELLULAR IMMUNOLOGY
Volume 266, Issue 1, Pages 98-103Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.cellimm.2010.09.003
Keywords
Transcutaneous immunization; gp100; Cancer vaccine
Categories
Funding
- NIH [1 R21 CA114160-01A1]
- NATIONAL CANCER INSTITUTE [R21CA114160] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The objective of this study was to evaluate the potential of transcutaneous immunization with tumor antigen to induce cell-mediated immunity. For this purpose, hydrophilic recombinant gp100 protein (HR-gp100) was topically applied on human intact skin in vitro, and used as a vaccine in a mouse model. We demonstrate that HR-gp100 permeates into human skin, and is processed and presented by human dendritic cells. In a mouse model, an HR-gp100-based vaccine triggered antigen-specific T cell responses, as shown by proliferation assays, ELISA and intracellular staining for IFN-gamma. Transcutaneous antigen delivery may provide a safe, simple and effective method to elicit cell-mediated immunity. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available